Enliven Therapeutics (ELVN) Short Interest
Nasdaq • ELVN • US29337E1029
47.25Last close
Market Closed
As of Oct 21, 2026, ORTEX estimates 17% of free float is sold short, 8 days to cover, cost to borrow 0.5%.
About this data: ELVN short interest, cost to borrow and days to cover
This page tracks how heavily Enliven Therapeutics (Nasdaq:ELVN) is being shorted: ORTEX's daily short interest estimate, the cost to borrow the shares, utilization of the lendable supply and days to cover, next to the official exchange-reported figure.
- Short interest
- The number of shares that have been sold short and not yet bought back, usually shown as a percentage of free float (the shares available to trade). ORTEX estimates it every day from securities-lending data, instead of waiting for exchange reports that are published only twice a month and about two weeks late.
- Cost to borrow
- The annualised fee a short seller pays to borrow the shares, as a percentage of the position's value. A rising cost to borrow means lendable shares are getting scarce and holding the short is getting more expensive.
- Utilization
- The share of the lendable supply of a stock that is currently on loan. Close to 100% means almost no shares are left to borrow.
- Days to cover
- Short interest divided by average daily trading volume: roughly how many days of normal trading it would take for every short seller to buy back their shares.
- Exchange-reported short interest
- The official figure published by the exchange or regulator (in the US, FINRA twice a month). It is accurate but delayed, which is the gap the ORTEX daily and intraday estimates fill.
Source: ORTEX. Some figures are limited on the free view; live data and full history are part of ORTEX Advanced.
ELVN key data
Enliven Therapeutics (Nasdaq: ELVN) has a market capitalization of $3.47B. Last close $47.25 (as of 2026-11-05); 52-week range $14.79 to $62.32. ORTEX data as of 2026-10-21: short interest is 16.98% of free float, 8 days to cover and the average cost to borrow is 0.5%.